发明名称 |
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
摘要 |
Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious antipsychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis. |
申请公布号 |
EP2009000(A1) |
申请公布日期 |
2008.12.31 |
申请号 |
EP20080015449 |
申请日期 |
2004.01.15 |
申请人 |
ACADIA PHARMACEUTICALS INC. |
发明人 |
WEINER, M.DAVID;DAVIS, ROBERT E.;BRANN, MARK R.;NASH, NORMAN;ANDERSSON, CARL-MAGNUS A.;ULDAM, ALLAN K. |
分类号 |
C07D211/06;A61K31/198;A61K31/445;A61K31/4468;A61K31/5513;A61K39/08;A61K45/06;A61P25/06;A61P25/14;A61P25/16;A61P25/18;A61P25/24;A61P25/28;C07D211/58 |
主分类号 |
C07D211/06 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|